drugset / Trial / NCT01020799

AZD7268 Safety and Tolerability Study

NCT01020799

Phase 2 Completed 247 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo.

Timeline

Start
2009-11
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD7268 Small molecule 15 mg Oral
Comparator Escitalopram Small molecule 20 mg Oral